Motley Fool  Aug 27  Comment 
Highlights from Regeneron's conference call.
SeekingAlpha  Aug 26  Comment 
By DoctoRx: Background: On August 8, I did my first and only article on Regeneron (NASDAQ:REGN), titled The Case That Regeneron May Be Significantly Undervalued. This company has a rapidly-growing franchise for retinal problems and a large...
Jutia Group  Aug 19  Comment 
[PR Newswire] - TARRYTOWN, N.Y., Aug. 19, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management presentations at the following investor conferences: Sanofi and Regeneron will host ... Read more on this. ...
CNNMoney.com  Aug 18  Comment 
Leonard Schleifer is a billionaire and CEO of Regeneron, one of the top biotech companies in the world.
Market Intelligence Center  Aug 14  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithms on Regeneron Pharmaceuticals Inc (REGN) could yield about 6.90% (25.18% annualized, for comparison purposes only) in 100 days. Pair a long position in the stock with...
SeekingAlpha  Aug 8  Comment 
ByDoctoRx: Background: In biotech, a company that begins bringing in revenues - and thus ceases to be a development-stage company - enters into a phase where it is premature to be viewed by traditional P/E and related metrics. When the company is...
newratings.com  Aug 6  Comment 
PARIS (dpa-AFX) - Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia. Results from the four ongoing trials, all of which met...
SeekingAlpha  Aug 5  Comment 
Regeneron Pharmaceuticals (NASDAQ:REGN) Q2 2014 Earnings Call August 05, 2014 8:30 am ET Executives Michael Aberman - Vice President of Strategy & Investor Relations Leonard S. Schleifer - Co-Founder, Chief Executive Officer,...
Benzinga  Aug 5  Comment 
Regeneron (NASDAQ: REGN) moved higher on the Tuesday session to top at $337 from the $313 open. The stock faded towards the later part of the session. In a mid-day note on Tuesday, Deutsche Bank reiterates its buy rating, and raised their...
TheStreet.com  Aug 5  Comment 
NEW YORK (TheStreet) -- Regeneron  rose in morning trading Tuesday after the biotechnology company reported second-quarter earnings that surpassed analysts' expectations thanks to sales of its macular degeneration drug Eylea. The company...


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki